Endogena Therapeutics � EA-2353 Retinitis Pigmentosa

Endogena Therapeutics, founded by Matthias Steger MD PhD, is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs that have deteriorated due to aging and genetic diseases. Endogena is doing a step-by-step test on a drug called EA-2353 to see if it’s safe, if people can handle it well, and if it works well in people with Retinitis Pigmentosa (RP) (a kind of eye condition). They’ll inject the drug directly into one eye (the eye they’re studying) of the patient. EA-2353 will be tested on up to four different groups of people. The development of this drug is being fast-tracked by the FDA as it has the potential to fulfill and severly undermet need. ClinicalTrials.gov Identifier: NCT05392751